Zydus Cadila gets USFDA nod to Butalbital, Acetaminophen, Caffeine Tablets to treat tension headache
This combination of medication is used to treat symptom complex of tension (or muscle contraction) headache.
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Butalbital, Acetaminophen and Caffeine Tablets (US RLD: Butalbital, Acetaminophen and Caffeine Tablets) in the strengths 50mg/325mg/40 mg.
This combination of medication is used to treat symptom complex of tension (or muscle contraction) headache. The drug will be manufactured at Nesher Pharma's manufacturing facility at St. Louis, USA.
The group now has 294 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila gets Mexican nod for clinical trials of Pegylated Interferon alpha-2b
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Zydus Cadila aims to complete trial of COVID-19 vaccine by March
